X-Chem delivers excellence, innovation and efficiency at each stage of drug discovery. Since 2012, our medicinal chemists have been named as co-inventors on 24 projects, have filed over 100 patents and published more than 65 scientific papers. Our impressive track record includes 17 compounds reaching IND-enabling toxicology studies and seven compounds progressing to Phase I clinical trials or beyond.

Hit → Lead → Candidate: Click through our proven track record of reliability, efficiency and success.

Kinases
PINK1 activator, EC50=ca. 500 nM
Target: PINK1 activator, EC50=ca. 500 nM
Therapy Area: Neurodegeneration
Protein-Protein Interaction
Bromodomain
Target: Bromodomain
Therapy Area: Cancer/Autoimmune/Inflammation
Protein-Protein Interaction
Bromodomain
Target: Bromodomain
Therapy Area: Cancer/Autoimmune/Inflammation
Protein-Protein Interaction
Bromodomain
Target: Bromodomain
Therapy Area: Cancer/Autoimmune/Inflammation
Protein-Protein Interaction
Bromodomain
Target: Bromodomain
Therapy Area: Inflammation
Receptors
PAR2
Target: PAR2
Therapy Area: Cancer
Protein-Protein Interaction
KEAP1
Target: KEAP1
Therapy Area: CNS
Receptors
CXCR7
Target: CXCR7
Therapy Area: Cardioprotection
Enzymes
EED & PRC2 Modulators
Target: EED & PRC2 Modulators
Therapy Area: Sickle Celled Anemia
Protein-Protein Interaction
NLRP3
Target: NLRP3
Therapy Area: Inflammation
Kinases
PINK1
Target: PINK1
Therapy Area: CNS
Transcription Factors
FOXO1
Target: FOXO1
Therapy Area: Diabetes
Receptors
Sodium Channel
Target: H4
Therapy Area: Inflammation/Pain/Autoimmune
ION Channels
Sodium Channel
Target: Sodium Channel
Therapy Area: CNS